The News

Innate Pharma

08/02/2007

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announced today that IPH 2101 (NN 1975), a fully human monoclonal antibody developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans (in January 2007), as part of a Phase I clinical trial for patients with acute myeloid leukemia (“AML”).

The trial is being performed at two of the largest cancer clinical research centers in France, the Institut Paoli-Calmettes in Marseille and the Institut Gustave-Roussy in Paris.

Innate Pharma received an undisclosed payment for this first clinical trial milestone.

2007

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com